

INTERCEPT® Blood System for Platelets Pathogen Reduction System

Sample SBAR:

Situation:

INTERCEPT® Blood System treated (psoralen-treated) platelets are pathogen reduced platelets and are an FDA approved alternative to conventional irradiated platelets for the prevention of transfusion-associated graft-versus-host disease (TA-GVHD).¹

Background:

INTERCEPT treated pathogen reduced platelets will be available at <Hospital name> starting on <Date>. INTERCEPT treated platelets are Apheresis Single Donor platelets treated with a psoralen compound activated by UVA light to reduce the risk of transfusion-transmitted pathogens, including bacteria, viruses, parasites, and leukocytes (T-cells).

Assessment:

Pathogen reduction by INTERCEPT treatment (psoralen treatment) is FDA approved as an alternative to gamma irradiation for the prevention of TA-GVHD. The platelet bag for psoralen treated platelets is slightly larger than the current bag but the platelet volume is the same, and there is no indication of irradiation or RadSure sticker on the bag.

Recommendation:

Use INTERCEPT treated platelets, as an approved alternative to irradiated platelets. An order for irradiated platelets may be filled with INTERCEPT (psoralen-treated) platelets or conventional irradiated platelets interchangeably.

References

1. INTERCEPT Blood System for Platelets [Package Insert]. Concord, CA: Cerus Corporation; July 17, 2018.